AtaGenix Laboratories
AtaGenix leverages decades of expertise and a full yeast expression toolbox to deliver high-quality, cost-effective recombinant proteins optimized for research, diagnostics, and therapeutic development.
Flexible host options
Choose between Pichia pastoris and Saccharomyces cerevisiae for your protein expression.
Complete yeast expression toolbox
We provide multiple strains of P. pastoris and S. cerevisiae to maximize yield, solubility, and biological activity.
Unrivaled production expertise
With 1,500+ successful protein expressions, our team delivers consistent, reliable outcomes.
Integrated gene-to-protein solution
From codon optimization and cloning to expression, purification, and QC—we are your end-to-end partner.
PhD account managers
Each project is guided by a dedicated PhD account manager for scientific precision and clear communication.
Cost-effective and scalable
Yeast systems combine fast growth with high yields, enabling efficient pilots and scale-up.
Expression vector construction (optional)
- Gene design including codon optimization
- Gene synthesis
- Subcloning into a yeast expression vector
Small-scale protein expression
- Transformation and selection of yeast clones
- Identification of top-expressing clones
- Expression optimization
- SDS-PAGE and Western blot (as required)
- Pilot purification tests
Protein expression scale-up and purification
- Fermentation under optimized conditions
- Chromatography-based purification
- QC including SDS-PAGE, WB, SEC, HPLC, and endotoxin testing
Step | Content | Timeline | Deliverables |
Protein pilot | - Transformation of yeast cells - Clone screening for best expressers - Expression optimization - Pilot purification |
4 to 5 weeks | - Test protein sample |
Transient protein expression and purification | - Large-scale protein expression - Purification - QC analysis: SDS-PAGE, concentration |
~2 weeks | - Purified protein - Detailed QC report |
Optional needs including codon optimization for protein expression and subcloning in a yeast expression vector
- Chromatography workflows for protein expression
- DNA, HPLC, endotoxin assays
- Analytics: WB, analytical SEC
A 2017 study developed a high-affinity anti-HE4 monoclonal antibody (9C3) using AtaGenix’s advanced mammalian expression and hybridoma platforms. This breakthrough enhances ovarian cancer diagnostics by targeting the HE4 biomarker with high specificity, offering potential for early detection and therapy.
This article highlights a 2021 Small Methods study that identified immunogenic peptides in the SARS-CoV-2 spike protein and isolated neutralizing monoclonal antibodies from COVID-19 patients. The research pinpointed key RBM epitopes (S431-454, S470-486, S501-515), with S470-486 emerging as an immunodominant target for diagnostics and therapeutics. Using phage display and ScFv libraries, the study validated epitope mapping and antibody functionality. Supported by AtaGenix’s expertise in phage display, protein expression, and assay development, this breakthrough offers a scalable approach for combating emerging viral pathogens, updated as of August 24, 2025.